

**FOR FURTHER INFORMATION CONTACT:**

Chris Sitbon (907) 271-3226.

Authority: 43 CFR 2650.7(d).

Chris Sitbon,

Land Law Examiner.

[FR Doc. 01-25529 Filed 10-10-01; 8:45 am]

BILLING CODE 4310-84-P

**DEPARTMENT OF THE INTERIOR****Bureau of Land Management****Emergency Temporary Closure for All Motorized Vehicles on Public Land in the Silver Creek Ridge Area, Sublette County, WY****AGENCY:** Bureau of Land Management, Interior.**ACTION:** Notice; correction.

**SUMMARY:** The Bureau of Land Management published a notice in the **Federal Register** of October 1, 2001, concerning the closure of the Silver Creek Ridge area to all motorized vehicles. The notice contained an incorrect legal description.

**FOR FURTHER INFORMATION CONTACT:** Bill Wadsworth (307) 367-5341.

**Correction**

In the **Federal Register** of October 1, 2001, in FR Doc. 01-2447 on page 49973, in the third column, 2nd paragraph under the **SUPPLEMENTARY INFORMATION**, correct the legal description to read:

T. 32 N., R. 107 W., Section 24, E½

Dated: October 3, 2001.

Priscilla Mecham,

Field Manager.

[FR Doc. 01-25562 Filed 10-10-01; 8:45 am]

BILLING CODE 4310-DN-M

**DEPARTMENT OF THE INTERIOR****Bureau of Land Management**

[CA-610-5101-ER-XBCH; CA-17918]

**Notice of Right-of-Way Application; California****AGENCY:** Bureau of Land Management, Interior.**ACTION:** Notice.

**SUMMARY:** An application, serialized as CA-17918, was received from the Kern River Transmission Company (Kern River) for a natural gas pipeline right-of-way from Kern River's Opal Meter Station in Southwest Wyoming, across Utah and Nevada to the Kern River Daggett Compressor Station in Southern California.

Notice is hereby given that, pursuant to section 28 of the Mineral Leasing Act of 1920 (30 U.S.C. 185), as amended by the Act of November 16, 1973, (37 Stat. 576), Kern River has applied for a right-of-way for 42 inch and 36 inch diameter pipelines on approximately 345 miles of Federal lands. The pipeline has a total length of approximately 720 miles. The project would parallel/loop an existing pipeline and will accommodate projected volume needs. The legal land description is not presented here due to its length. Maps of the project are available at Bureau of Land Management and Forest Service offices located on the route.

The purpose of this notice is to inform the public of the receipt of the application and that the Bureau of Land Management will be making a decision on approval of the right-of-way, and if so, under what terms and conditions. An Environmental Impact Statement is being prepared under direction of the Federal Energy Regulatory Commission, lead agency for the project. The Bureau of Land Management is a cooperating agency.

Additional information can be obtained by contacting Jerry Crockford at (505) 599-6333 or on electronic mail at [jcrockfo@nm.blm.gov](mailto:jcrockfo@nm.blm.gov).

Dated: August 17, 2001.

James Wesley Abbott,

Acting State Director, California.

[FR Doc. 01-25528 Filed 10-10-01; 8:45 am]

BILLING CODE 4310-40-P

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 25, 2001, Dupont Pharmaceuticals, 1000 Stewart Avenue, Garden City, New York 11530, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

| Drug                     | Schedule |
|--------------------------|----------|
| Oxycodone (9143) .....   | II       |
| Hydrocodone (9193) ..... | II       |
| Oxymorphone (9652) ..... | II       |

The firm plans to manufacture the listed controlled substances to make finished products.

Any other such applicant and any person who is presently registered with

DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than December 10, 2001.

Dated: October 2, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 01-25443 Filed 10-10-01; 8:45 am]

BILLING CODE 4410-09-M

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated September 26, 2000, and published in the **Federal Register** on October 13, 2000, (65 FR 60978), Guilford Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of cocaine (9041), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture methyl-3-beta-(4-trimethylstannylphenyl)-tropane-2-carboxylate as a final intermediate for the production of dopascan injection.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Guilford Pharmaceuticals to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated the firm on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm

for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: September 25, 2001.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 01-25447 Filed 10-10-01; 8:45 am]

**BILLING CODE 4410-09-M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 6, 2001, Lifepoint, Inc., 1205 S. Dupont Street, Ontario, California 91761, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

| Drug   | Schedule |
|--|----------|
| Tetrahydrocannabinols (7370) .....             | I        |
| 3,4-Methylenedioxyamphetamine (7400).          | I        |
| 3,4-Methylenedioxy-N-ethylamphetamine (7404).  | I        |
| 3,4-Methylenedioxy-N-methylamphetamine (7405). | I        |
| Amphetamine (1100) .....                       | II       |
| Methamphetamine (1105) .....                   | II       |
| Phencyclidine (7471) .....                     | II       |
| Benzoyllecgonine (9180) .....                  | II       |
| Morphine (9300) .....                          | II       |

The firm plans to use gram quantities of the listed controlled substances to manufacture drug abuse test kits.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCF), and must be filed no later than December 10, 2001.

Dated: October 2, 2001.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 01-25445 Filed 10-10-01; 8:45 am]

**BILLING CODE 4410-09-M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this notice that only July 25, 2001, Norac Company, Inc., 405 S. Motor Avenue, Azusa, California 91702, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of tetrahydrocannabinols (7370), a basic class of controlled substance listed in Schedule I.

The firm plans to manufacture medication for the treatment of AIDS wasting syndrome and as an antiemetic.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Offices of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than December 10, 2001.

Dated: October 2, 2001.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 01-25446 Filed 10-10-01; 8:45 am]

**BILLING CODE 4410-09-M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 26, 2001, Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

| Drug                     | Schedule |
|--------------------------|----------|
| Amphetamine (1100) ..... | II       |
| Codeine (9050) .....     | II       |
| Oxycodone (9143) .....   | II       |
| Hydrocodone (9193) ..... | II       |
| Morphine (9300) .....    | II       |
| Thebaine (9333) .....    | II       |

| Drug                  | Schedule |
|-----------------------|----------|
| Fentanyl (9801) ..... | II       |

The firm plans to support its other manufacturing facility with manufacturing and analytical testing.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than December 10, 2001.

Dated: October 02, 2001.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 01-25444 Filed 10-10-01; 8:45 am]

**BILLING CODE 4410-09-M**

## DEPARTMENT OF JUSTICE

### Immigration and Naturalization Service

#### Agency Information Collection Activities: Comment Request

**ACTION:** Notice of information collection under review; employment authorization document.

The Department of Justice, Immigration and Naturalization Service has submitted the following information collection request (ICR) for review and clearance in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for sixty days until December 10, 2001.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information should address one or more of the following four points:

(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;